Figure 3

Cumulative incidence of NODM according to the statin intensity and dose. (A) Cumulative incidence of NODM according to the atorvastatin intensity. Patients treated with high-intensity atorvastatin showed a significantly higher cumulative incidence of NODM compared to the moderate-intensity atorvastatin group (7.2% vs. 5.8%, P = 0.002). (B) Cumulative incidence of NODM according to the atorvastatin dose. Patients treated with the 80 mg of atorvastatin had the highest cumulative incidence of NODM, followed by those on 40 mg, 20 mg and 10 mg of atorvastatin (7.7% vs. 7.1% vs. 5.8% vs. 5.7%, respectively, P = 0.484) (C) Cumulative incidence of NODM according to the rosuvastatin intensity. Patients treated with high-intensity rosuvastatin had a significantly higher cumulative incidence of NODM compared to the moderate-intensity rosuvastatin group (8.3% vs. 5.8%, P = 0.004). (D) Cumulative incidence of NODM according to the rosuvastatin Dose. Patients treated with the 20 mg of rosuvastatin showed the highest cumulative incidence of NODM, followed by 10 mg, 5 mg of rosuvastatin (8.3% vs. 5.5% vs. 2.8%, P = 0.008). NODM new-onset diabetes mellitus.